NIH highlights key tips and facts about glaucoma

NewsGuard 100/100 Score

January is Glaucoma Awareness Month. The National Eye Institute, part of NIH, is highlighting key facts about this blinding disease, important tips for prevention and treatment, and research updates you may not know about.

1) More than 2.7 million Americans over age 40 have glaucoma. That number is estimated to more than double by 2050. Though glaucoma is the second leading cause of blindness in developed countries, increased awareness and ongoing research may reduce the health burden of glaucoma.

2) Anyone can develop glaucoma. Though it's more common in people over the age of 45, babies and children can get a rare form of early onset glaucoma. The following groups are at higher risk of glaucoma:
- African Americans over age 40
- People over age 60, especially Mexican Americans
- People with a family history of glaucoma

3) Getting a comprehensive dilated eye exam is the only way to catch glaucoma early. During a comprehensive dilated eye exam, drops are placed in your eyes to dilate, or widen, the pupil. Your eye care professional uses a special magnifying lens to examine the back of your eye and look for signs of damage or problems. People at higher risk of glaucoma should usually be examined every one to two years.

4) Don't wait for symptoms. Lack of awareness and lack of symptoms prevent people from getting glaucoma diagnosed early, notes Jullia Rosdahl, M.D., Ph.D., of the National Eye Health Education Program and Duke Eye Center. Without treatment, people with glaucoma will slowly lose their peripheral (side) vision. Over time, central (straight-ahead) vision is also affected.

5) Glaucoma damages the eye's optic nerve. The optic nerve is like a data cable coming out of the back of your eye. It carries visual information to your brain. Glaucoma damages the nerve cells or "wires" in the cable, disrupting the flow of visual information.

6) Once glaucoma damages your optic nerve, lost vision cannot be restored. Early detection combined with treatment can slow or stop glaucoma progression.

7) Eye pressure is a major risk factor for glaucoma. However, not every person with increased eye pressure will develop glaucoma, and glaucoma can develop without increased eye pressure.

8) The only clinically proven treatment for glaucoma is to lower eye pressure. Some medicines cause the eye to make less fluid. Others lower pressure by helping fluid drain from the eye.

9) A new drug-delivery system is currently being tested. NEI-funded researchers are testing a drug-dispensing contact lens that may be easier to use than drops or pills.

10) Studies in the laboratory and with patients are making key discoveries and giving new hope.
• Researchers at NEI are studying how to protect retinal ganglion cells, the cells that make up the optic nerve.
• NEI-funded researchers at Indiana University-Purdue University Indianapolis turned patient-derived stem cells into retinal ganglion cells.
• Recent NEI-funded analysis identified three additional genes that contribute to the most common type of glaucoma.
• Scientists at the Medical College of Georgia at Augusta University found that high expression of a short gene may contribute to destructive eye pressures in glaucoma.
• NEI-funded researchers at the Icahn School of Medicine at Mount Sinai developed a method to test potential glaucoma treatments and study disease progression

Get all the facts about glaucoma from the National Eye Institute, and spread awareness with NEI's National Eye Health Education Program. The NEI does not pay for individual eye care, but if you are in need of financial aid to assess or treat an eye problem such as glaucoma, these programs may help: https://nei.nih.gov/health/financialaid.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis